Keyphrases
Multiple Sclerosis
100%
Ocrelizumab
100%
Treatment Options
9%
Dose Escalation
9%
Pharmacokinetics
9%
Previously Treated
9%
Safety Data
9%
Nave
9%
New Patients
9%
Tolerability
9%
Immunogenicity
9%
Progressive multiple Sclerosis
9%
Intravenous Dose
9%
Expanded Disability Status Scale
9%
Additional Treatment
9%
Continuation Phase
9%
Dose Finding
9%
Single Ascending Dose
9%
Pharmacokinetic Data
9%
Treatment Flexibility
9%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Ocrelizumab
100%
Pharmacokinetics
18%
Tolerability
9%
Immunogenicity
9%
Expanded Disability Status Scale
9%
Subcutaneous Injection
9%
Immunology and Microbiology
Multiple Sclerosis
100%
Ocrelizumab
100%
Pharmacokinetics
18%
Immunogenicity
9%
Expanded Disability Status Scale
9%
Primary Progressive Multiple Sclerosis
9%
Neuroscience
Multiple Sclerosis
100%
Ocrelizumab
100%
Pharmacokinetics
18%
Expanded Disability Status Scale
9%
Primary Progressive Multiple Sclerosis
9%